Benzinga | Nov 10, 2021 06:20PM EST

Clearside Biomedical Q3 EPS $(0.08), Inline, Sales $3.07M Beat $2.58M Estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 60 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $3.07 million which beat the analyst consensus estimate of $2.58 million by 19.15 percent. This is a 10.43 percent decrease over sales of $3.43 million the same period last year.